Skip to content
Open access

Small-Molecule Modulators of HIPK4 Activity and Proteostasis

Oct 2026 · Journal of the American Chemical Society · Vol 148, pp. 44182 - 44207 · 0 citations · 53 references
Medicine

TL;DR

The discovery of a cyanoquinoline-based series of HIPK4 inhibitors with nanomolar potency is reported, establishing cyanoquinoline ligands as a new chemotype for probing HIPK4 biology and advancing male contraceptive discovery.

Abstract

Homeodomain-interacting protein kinase 4 (HIPK4) is a dual-specificity kinase that is predominantly expressed in differentiating spermatids, required for sperm development, and a promising target for nonhormonal male contraception. Genetic and functional studies have established an essential role for HIPK4 in spermiogenesis, where it acts at least in part through regulation of the F-actin-scaffolded acroplaxome during spermatid head shaping. The direct molecular targets of HIPK4 and their downstream effectors remain poorly defined, and small-molecule probes would be versatile tools for further investigating HIPK4 functions. Synthetic HIPK4 ligands could also be valuable leads for the development of nonhormonal male contraceptives. Here, we report the discovery of a cyanoquinoline-based series of HIPK4 inhibitors with nanomolar potency. Our lead compounds are selective for HIPK4, both within the HIPK family and across the broader kinome, establishing this scaffold as a useful starting point for probe and lead development. Unexpectedly, we found that a subset of these cyanoquinolines also perturbs HIPK4 proteostasis in a cell-type-specific manner. In spermatids, these compounds induce the formation of detergent-insoluble HIPK4 aggregates and promote interactions between this kinase and the autophagy receptor Tax1-binding protein 1 (TAX1BP1), potentially reinforcing a native mechanism of HIPK4 regulation. Together, our findings establish cyanoquinoline ligands as a new chemotype for probing HIPK4 biology and advancing male contraceptive discovery.

Read PDF

Similar papers

Open access Oct 2026

PI3Kδ is selectively inhibited by roginolisib by stabilizing the C-terminal helix kα12

Phosphoinositide 3-kinases (PI3Ks) are major regulators of cell growth, proliferation and signalling, constituting key therapeutic targets in cancer, inflammation, and other diseases. Individual class I PI3K isoforms control key cellular functions, imposing the need to generate isoform-specific inhibition for therapeut...

O. Vadas, S. Tiede, Maria Chaouki et al. · 1 citation
Open access Oct 2026

Development of Next-Generation ALDH1B1 Inhibitors with Enhanced Pharmacological and Functional Properties.

ALDH1B1 is a mitochondrial aldehyde dehydrogenase required for the survival of stem-like colorectal and pancreatic cancer cells. Isoform-selective guanidinyl antagonists of aldehyde dehydrogenases (IGUANAs) have been developed for ALDH1B1, and here we describe structure-activity relationship (SAR) studies of three scaf...

A. Tarhan, Zhi-Ping Feng, Daniel Fernández et al. · 0 citations
Sep 2026

Development of Isoform-Selective GRP78 Inhibitors from a Direct-to-Biology Strategy.

The development of isoform-selective HSP70 inhibitors remains challenging due to the high conservation of this chaperone family. Continuing our efforts to target the peptide-binding pocket within the substrate-binding domain (SBD) of GRP78 (BiP/HSPA5), we identified compound 12 using a Direct-to-Biology (D2B) strategy....

Xiao-Yi Zhu, Qiu Li, Ke Wang et al. · 0 citations
Open access Sep 2026

Systematic identification of p11 as a signaling modulator across the GPCRome

It is demonstrated that p11 recruitment to GPCRs is promoted by an active receptor conformation, and p11 acts as an amplifier of endogenous PAR2 signaling.

Marcus Saarinen, Ilana B. Kotliar, Inga Höffkes et al. · 0 citations
Review Sep 2026

Targeting Transcriptional Coactivators p300/CBP: Small-Molecule Inhibitors or Bifunctional Proximity-Inducing Modalities?

p300 and its paralog CBP are multifunctional transcriptional coactivators that play central roles in epigenetic regulation by integrating diverse signaling pathways. Dysregulation of p300/CBP is closely linked to cancer and other diseases, rendering them attractive therapeutic targets. Several small-molecule inhibitors...

Zong-Lin Chen, Xun Huang, Ying-Xia Li · 0 citations
Open access Oct 2026

Development of A10P3C, an isoform-selective inhibitor of EGLN2, for targeting breast cancer.

Oxygen sensing signaling is mainly mediated by EGLN prolyl hydroxylases, which plays important roles in physiology and diseases. Among them, EGLN2 plays an oncogenic role in breast cancer. However, the development of isoform-selective EGLN2 inhibitors remains a major challenge. Here, we report the identification of A10...

Qian Liang, Hui-Min Zhu, Bang-Chieh Huang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.